Incyte Genomics and Genomic Health Announce Collaboration Palo Alto, CA, May 7, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY) and Genomic Health, Inc., today announced a collaboration that will utilize Incyte's industry-leading platform of genomic and proteomic databases, functional genomic technologies, and intellectual property. Through this collaboration, Genomic Health will have access to Incyte's LifeSeq® Gold and BioKnowledge™ databases. In addition, Genomic Health will receive licenses to certain of Incyte's intellectual property and will fund a research and development collaboration with Incyte to develop new consumer applications for genomics. The Incyte databases and intellectual property will be used to facilitate Genomic Health's development of products. Although financial terms were not disclosed, amounts paid by Genomic Health under the collaboration agreements are similar to those paid in other unrelated third party agreements. Incyte also participated in the latest round of financing of Genomic Health. Genomic Health, Inc., located in Palo Alto, CA, is new venture founded by Randy Scott (co-founder of Incyte Genomics), Joffre Baker (Genentech), Steven Shak (Genentech), Gene Early (The Beracah Group Ltd.), and Patrick Terry (PXE International). Investors include Kleiner Perkins Caufield & Byers; Versant Ventures; Baker Tisch Investments, and CHL Medical Partners along with Incyte. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the ability to predict a drug's behavior, efficacy, and side effects, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including utilization of the databases in pharmaceutical research and product development; ability to meet production requirements; the impact of technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-K for the year ended December 31, 2000. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements.